O-1871

Synthetic cannabinoid
| O-1871
| |
|---|---|
| Chemical nomenclature | |
| IUPAC name | (6aR,10aR)-3-(hydroxymethyl)-6,6-dimethyl-9-pentyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol
|
| Identifiers | |
| CAS Number | 30251-30-0 |
| PubChem | 3084166
|
| ChemSpider | 2340840
|
| ChEMBL | 2106020 |
| Chemical data
| |
| Chemical formula | C21H30O3
|
| SMILES | CCCCCC1=CC2=C(C3C(C(C)(C)CC3)C(OC2=C1)CO)O
|
O-1871 is a synthetic cannabinoid that is structurally related to tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. It is part of a class of compounds known as cannabinoids, which interact with the endocannabinoid system in the body.
Chemical Structure[edit]
O-1871 has the IUPAC name (6aR,10aR)-3-(hydroxymethyl)-6,6-dimethyl-9-pentyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol. Its chemical structure is similar to that of THC, with modifications that include a hydroxymethyl group and a pentyl side chain.
Pharmacology[edit]
O-1871 acts on the cannabinoid receptors in the central nervous system and peripheral nervous system. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including pain, mood, and appetite.
Research and Applications[edit]
Research on O-1871 is primarily focused on its potential therapeutic applications and its effects on the endocannabinoid system. Studies have investigated its potential use in treating conditions such as chronic pain, inflammation, and neurological disorders.
Legal Status[edit]
The legal status of O-1871 varies by country. In some jurisdictions, it may be classified as a controlled substance due to its structural similarity to THC and its potential for psychoactive effects.
See Also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian